Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial

10.1080/21645515.2020.1861875

Saved in:

Bibliographic Details
Main Authors:	Eujung Juliana Park, SOPHIA ARCHULETA, May-Lin Helen Oh, LYNETTE PEI-CHI SHEK, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon
Other Authors:	MEDICINE
Format:	Article
Published:	Taylor & Francis 2021
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/194505
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-194505
record_format	dspace
spelling	sg-nus-scholar.10635-1945052024-11-09T00:18:55Z Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial Eujung Juliana Park SOPHIA ARCHULETA May-Lin Helen Oh LYNETTE PEI-CHI SHEK Hao Wang Matthew Bonaparte Carina Frago Alain Bouckenooghe Frederique Jantet-Blaudez Sarah Begue Sophie Gimenez-Fourage Anke Pagnon MEDICINE PAEDIATRICS 10.1080/21645515.2020.1861875 Human Vaccines & Immunotherapeutics 17 7 2107-2116 2021-07-20T09:38:46Z 2021-07-20T09:38:46Z 2021-02-24 Article Eujung Juliana Park, SOPHIA ARCHULETA, May-Lin Helen Oh, LYNETTE PEI-CHI SHEK, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon (2021-02-24). Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial. Human Vaccines & Immunotherapeutics 17 (7) : 2107-2116. ScholarBank@NUS Repository. https://doi.org/10.1080/21645515.2020.1861875 21645515 https://scholarbank.nus.edu.sg/handle/10635/194505 Taylor & Francis Taylor & Francis
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
description	10.1080/21645515.2020.1861875
author2	MEDICINE
author_facet	MEDICINE Eujung Juliana Park SOPHIA ARCHULETA May-Lin Helen Oh LYNETTE PEI-CHI SHEK Hao Wang Matthew Bonaparte Carina Frago Alain Bouckenooghe Frederique Jantet-Blaudez Sarah Begue Sophie Gimenez-Fourage Anke Pagnon
format	Article
author	Eujung Juliana Park SOPHIA ARCHULETA May-Lin Helen Oh LYNETTE PEI-CHI SHEK Hao Wang Matthew Bonaparte Carina Frago Alain Bouckenooghe Frederique Jantet-Blaudez Sarah Begue Sophie Gimenez-Fourage Anke Pagnon
spellingShingle	Eujung Juliana Park SOPHIA ARCHULETA May-Lin Helen Oh LYNETTE PEI-CHI SHEK Hao Wang Matthew Bonaparte Carina Frago Alain Bouckenooghe Frederique Jantet-Blaudez Sarah Begue Sophie Gimenez-Fourage Anke Pagnon Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial
author_sort	Eujung Juliana Park
title	Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial
title_short	Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial
title_full	Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial
title_fullStr	Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial
title_full_unstemmed	Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial
title_sort	humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in singapore: 2-year follow-up of a randomized phase ii, placebo-controlled trial
publisher	Taylor & Francis
publishDate	2021
url	https://scholarbank.nus.edu.sg/handle/10635/194505
_version_	1821216737704542208

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized Phase II, placebo-controlled trial

Similar Items